StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies on Sarepta Therapeutics (SRPT): 'The risk/reward seems favorable'
September 24, 2026 1:26 PM
Jefferies analyst Yun Zhong reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
